A Prospective, Multicenter Trial of the VentrAssist Left Ventricular Assist Device for Bridge to Transplant: Safety and Efficacy

Esmore, Donald S.; Kaye, David M.; Spratt, Phillip; Larbalestier, Robert; Ruygrok, Peter; Tsui, Steven; Meyers, Deborah E.; Fiane, Arnt E.; Woodard, John

doi:10.1016/j.healun.2008.02.012

Cited by 86 publications

(63 citation statements)

References 21 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initially transplantation from intra-aortic balloon pump support, ventricular assists device [usually as left ventricular assist (LVAD) but occasionally biventricular assist (BiVAD)] as well as extracorporeal membrane oxygenation (ECMO) support is increasingly utilized as a "bridge" to transplant (60,69,70). Indeed, these advanced therapies may allow recovery of dysfunction of other organs (e.g., kidneys) and even allow participation in physical rehabilitation, improving the ability of the recipient to survive the transplant procedure (83).…”

Section: Heartmentioning

confidence: 99%

Exercise Limitation Following Transplantation

Williams

McKenna

2012

Comprehensive Physiology

View full text Add to dashboard Cite

Organ transplantation is one of the medical miracles or the 20th century. It has the capacity to substantially improve exercise performance and quality of life in patients who are severely limited with chronic organ failure. We focus on the most commonly performed solid‐organ transplants and describe peak exercise performance following recovery from transplantation. Across all of the common transplants, evaluated significant reduction in o 2 peak is seen (typically renal and liver 65%‐80% with heart and/or lung 50%‐60% of predicted). Those with the lowest o 2 peak pretransplant have the lowest o 2 peak posttransplant. Overall very few patients have a o 2 peak in the normal range. Investigation of the cause of the reduction of o 2 peak has identified many factors pre‐ and posttransplant that may contribute. These include organ‐specific factors in the otherwise well‐functioning allograft (e.g., chronotropic incompetence in heart transplantation) as well as allograft dysfunction itself (e.g., chronic lung allograft dysfunction). However, looking across all transplants, a pattern emerges. A low muscle mass with qualitative change in large exercising skeletal muscle groups is seen pretransplant. Many factor posttransplant aggravate these changes or prevent them recovering, especially calcineurin antagonist drugs which are key immunosuppressing agents. This results in the reduction of o 2 peak despite restoration of near normal function of the initially failing organ system. As such organ transplantation has provided an experiment of nature that has focused our attention on an important confounder of chronic organ failure‐skeletal muscle dysfunction. © 2012 American Physiological Society. Compr Physiol 2:1937‐1979, 2012.

show abstract

Section: Heartmentioning

confidence: 99%

Exercise Limitation Following Transplantation

Williams

McKenna

2012

Comprehensive Physiology

View full text Add to dashboard Cite

show abstract

“…These features, coupled with the lower number of revolutions per minute, should enhance durability in comparison with the second generation pumps. Examples of such third generation VADs are the VentrAssist VAD (Ventracor Ltd, Chatswood, New South Wales, Australia) 20 and the DuraHeart (Terumo, Somerset, New Jersey, USA). 21 …”

Section: Third Generation Vadsmentioning

confidence: 99%

“…12,13 The following criteria should generally be met prior to consideration of LVAD implant: clinical evidence of impaired end-organ perfusion with cardiac index <2 L/min/m2, pulmonary capillary wedge pressure >20 mmHg, and systolic blood pressure <80 mmHg despite maximal medical support, including inotropes and an intraaortic balloon pump, if indicated. 20 Although it is important to meet these criteria, LVAD implantation should be performed before extensive end-organ damage for maximal chance of success. 21 …”

Section: Bridge To Transplantationmentioning

confidence: 99%

Ventricular Assist Device: Emerging Modality for Long Term Cardiac Support

Shah¹,

Kommu²,

Bhuriya³

et al. 2011

New Aspects of Ventricular Assist Devices

View full text Add to dashboard Cite

“…A unique feature of the device is the titanium a magnetically suspended centrifugal pump that uses transcutaneous energy transfer system technology to be totally implantable. 35,36 Other devices in development and clinical trials that employ magnetic levitation technology include the Terumo DuraHeart TM (Terumo Heart Inc., Ann Arbor, MI), 37 the CorAide blood pump (The Cleveland Clinic Foundation, Cleveland, OH) 38,39 and the Heartware HVAD TM (HeartWare Ltd., Sydney, Australia). 40,41 vad complications.…”

Section: First-generation Vadsmentioning

confidence: 99%